Zeitschriftenartikel zum Thema „Gcb-Dlbcl“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Machen Sie sich mit Top-50 Zeitschriftenartikel für die Forschung zum Thema "Gcb-Dlbcl" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Sehen Sie die Zeitschriftenartikel für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.
Pukiat, Sulada, Nuttapong Ngamphaiboon, Pooja Advani, Julio Chavez, George Deeb, Anjana Elefante und Francisco J. Hernandez-Ilizaliturri. „BCL-2 Expression at the Time of Diagnosis Affects the Clinical Outcome of Patients with Germinal Center and Non-Germinal Center Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Chemo-Immunotherpy“. Blood 116, Nr. 21 (19.11.2010): 3130. http://dx.doi.org/10.1182/blood.v116.21.3130.3130.
Der volle Inhalt der QuelleTarius, Jenifer Marsela, Hermawan Istiadi, Ika Pawitra Miranti und Intan Rahmania Eka Dini. „THE CORRELATION BETWEEN CELL OF ORIGIN SUBTYPE WITH OVERALL SURVIVAL OF DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS IN KARIADI GENERAL HOSPITAL SEMARANG“. DIPONEGORO MEDICAL JOURNAL (JURNAL KEDOKTERAN DIPONEGORO) 9, Nr. 3 (12.05.2020): 252–58. http://dx.doi.org/10.14710/dmj.v9i3.27504.
Der volle Inhalt der QuelleGandhi, Shipra, Vishala T. Neppalli, George Deeb, Myron S. Czuczman und Francisco J. Hernandez-Ilizaliturri. „Distinct CD30 Expression Patterns In Germinal Center B-Cell (GCB) and Non-GCB Diffuse Large B-Cell Lymphoma (DLBCL)“. Blood 122, Nr. 21 (15.11.2013): 5064. http://dx.doi.org/10.1182/blood.v122.21.5064.5064.
Der volle Inhalt der QuelleHayama, Miyuki, Masataka Okamoto, Yuki Hagiwara, Ken Tanae, Mika Kohri, Naoki Takahashi, Tadashi Yoshino, Koichi Ohshima und Nozomi Niitsu. „Clinical Significance of Immunohistochemical Markers of Diffuse Large B-Cell Lymphoma In the Rituximab Era.“ Blood 116, Nr. 21 (19.11.2010): 1800. http://dx.doi.org/10.1182/blood.v116.21.1800.1800.
Der volle Inhalt der QuelleKharchenko, Yevgeniya, Tatyana Semiglazova, Anna Artemeva, Galina Kireeva, I. Polyatskin, Ilya Zyuzgin, Larisa Filatova, Yuliya Chudinovskikh, Margarita Motalkina und Yuliya Oleynik. „PROGNOSTIC IMPACT OF IMMUNOHISTOCHEMICAL AND MOLECULAR GENETIC MARKERS IN DIFFUSE LARGE B-CELL LYMPHOMA“. Problems in oncology 66, Nr. 1 (01.01.2020): 79–89. http://dx.doi.org/10.37469/0507-3758-2020-66-1-79-89.
Der volle Inhalt der QuelleAdhi Pangarsa, Eko, Desta Nur Ewika Ardini, Daniel Rizky, Kevin Tandarto, Hermawan Istiadi, Dik Puspasari, Budi Setiawan et al. „The association of Hypoxia-Inducible Factor-2α (HIF-2α) overexpression score with Germinal Center B-Cell Like (GCB) and Non-Germinal Center B-Cell Like (Non-GCB) subtypes of Diffuse Large B-cell Lymphoma (DLBCL)“. Bali Medical Journal 12, Nr. 3 (22.08.2023): 2456–62. http://dx.doi.org/10.15562/bmj.v12i3.4521.
Der volle Inhalt der QuelleMishima, Yuko, Masahiro Yokoyama, Noriko Nishimura, Kyoko Ueda, Tadahiro Gunji, Hideaki Nitta, Yoshiharu Kusano et al. „R-CHOP Therapy Cannot Overcome CD5 Positive Non-GCB Subtype of DLBCL“. Blood 126, Nr. 23 (03.12.2015): 1507. http://dx.doi.org/10.1182/blood.v126.23.1507.1507.
Der volle Inhalt der QuelleChavez, Julio, Mark Walsh, Francisco J. Hernandez-Ilizaliturri, Anjana Elefante und Myron S. Czuczman. „Classification of Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) According to the Han's Criteria Defines Two Groups of Patients with Different Clinical Outcomes Following Systemic Rituximab-Multi Agent Anthracycline-Based Therapy.“ Blood 114, Nr. 22 (20.11.2009): 623. http://dx.doi.org/10.1182/blood.v114.22.623.623.
Der volle Inhalt der QuelleVan Meerten, Tom, Renee Bouwstra, Yuan He, de Boer Janneke, Hilde Kooistra, Rudolf Fehrmann, Emanuele Ammatuna, Gerwin Huls und Edwin Bremer. „CD47 Expression Defines the Efficacy of Rituximab in Non-Germinal Center B-Cell (non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)“. Blood 132, Supplement 1 (29.11.2018): 2852. http://dx.doi.org/10.1182/blood-2018-99-114561.
Der volle Inhalt der QuelleNiitsu, Nozomi, Naoki Takahashi, Tadashi Yoshino, Masataka Okamoto und Shigeo Nakamura. „Prognostic Significance of EBV Association in Diffuse Large B-Cell Lymphoma in the Rituximab Era“. Blood 126, Nr. 23 (03.12.2015): 3911. http://dx.doi.org/10.1182/blood.v126.23.3911.3911.
Der volle Inhalt der QuelleAlam, SM Mahbubul, und Ahmed Khaled. „Immunophenotypic characteristics of Diffuse Large Bcell Lymphoma“. Bioresearch Communications 8, Nr. 1 (26.12.2021): 1049–52. http://dx.doi.org/10.3329/brc.v8i1.57043.
Der volle Inhalt der QuelleNooruddin, Zohra, Zenggang Pan, Lilyana Gross, Weitzenkamp David, Bradley M. Haverkos, Daniel A. Pollyea, Jonathan A. Gutman et al. „Post-Transplant Diffuse Large B Cell Lymphoma with Non Germinal Center B-Cell Subtype Frequently Lacks Programmed Cell Death Ligand (PD-L1) Overexpression Which May Influence Overall Outcomes“. Blood 128, Nr. 22 (02.12.2016): 3054. http://dx.doi.org/10.1182/blood.v128.22.3054.3054.
Der volle Inhalt der QuelleSlimani, Yasmine, Fouzia Hali und Fatima-Zohra El Fatoiki. „Triple-negative diffuse large B-cell lymphoma: A distinct entity“. Our Dermatology Online 12, Nr. 4 (19.10.2021): 427–29. http://dx.doi.org/10.7241/ourd.20214.17.
Der volle Inhalt der QuelleLossos, Izidore S., XiaoQing Lu, Feiying Ding, Manuel Rosado, Ash A. Alizadeh und Hovav Nechushtan. „Distinct IL-4 Intracellular Signaling in Germinal Center B-Cell like and Activated B-Cell like Diffuse Large B-Cell Lymphoma: Novel Opportunities for Therapeutic Interventions.“ Blood 104, Nr. 11 (16.11.2004): 244. http://dx.doi.org/10.1182/blood.v104.11.244.244.
Der volle Inhalt der QuelleCosta, Luciano J., Andrew L. Feldman, Ivana N. Micallef, David J. Inward, Patrick B. Johnston, Luis F. Porrata, Mark R. Litzow und Stephen M. Ansell. „Germinal Center B Cell and Non-Germinal Center B Cell-Like DLBCL Have Similar Clinical Features at the Time of Progression and Comparable Outcome Following Autologous HSC Transplantation.“ Blood 110, Nr. 11 (16.11.2007): 1901. http://dx.doi.org/10.1182/blood.v110.11.1901.1901.
Der volle Inhalt der QuelleJulianty, Patricia Fransisca, Maria Francisca Ham, Kusmardi Kusmardi und Agnes Stephanie Harahap. „CD30 Expression in Germinal Center B-cell-like and non-Germinal Center B-cell-like Subtypes of Diffuse Large B-cell Lymphoma“. Open Access Macedonian Journal of Medical Sciences 8, B (17.04.2020): 375–80. http://dx.doi.org/10.3889/oamjms.2020.4645.
Der volle Inhalt der QuelleLenz, Georg, George Wright, Sandeep Dave, Alexander Kohlmann, Wenming Xiao, John Powell, Hong Zhao et al. „Gene Expression Signatures Predict Overall Survial in Diffuse Large B Cell Lymphoma Treated with Rituximab and Chop-Like Chemotherapy.“ Blood 110, Nr. 11 (16.11.2007): 348. http://dx.doi.org/10.1182/blood.v110.11.348.348.
Der volle Inhalt der QuelleNechushtan, Hovav, Joseph D. Rosenblatt und Izidore S. Lossos. „IL-4 Affects Proliferation, Chemosensitivity-and Rituximab Sensitivity of Germinal Center B-Cell like (GCB) and Activated B-Cell like (ABC) Diffuse Large B-Cell Lymphoma Differently.“ Blood 104, Nr. 11 (16.11.2004): 242. http://dx.doi.org/10.1182/blood.v104.11.242.242.
Der volle Inhalt der QuelleLocatelli, Silvia L., Roberto Papait, Giuseppa Careddu, Ada Koschorke, Giuliano G. Stirparo, Monica Balzarotti, Luca Castagna, Armando Santoro und Carmelo Carlo-Stella. „Upregulation of Cereblon Expression By the DNA Methyltransferase Inhibitor Azacytidine Strongly Enhances Lenalidomide Cytotoxicity in Germinal Center B-Cell-like (GCB) and Activated B-Cell-like (ABC) Diffuse Large B-Cell Lymphoma (DLBCL)“. Blood 124, Nr. 21 (06.12.2014): 2253. http://dx.doi.org/10.1182/blood.v124.21.2253.2253.
Der volle Inhalt der QuelleKleinstern, Geffen, Dennis P. Robinson, Lisa M. Rimsza, Melissa C. Larson, Rebecca L. King, Grzegorz S. Nowakowski, Carrie A. Thompson et al. „Abstract 741: Evaluation of etiologic heterogeneity for risk of diffuse large B-cell lymphoma (DLBCL) subtype defined by cell-of-origin“. Cancer Research 82, Nr. 12_Supplement (15.06.2022): 741. http://dx.doi.org/10.1158/1538-7445.am2022-741.
Der volle Inhalt der QuelleFu, Kai, Dennis D. Weisenburger, William W. L. Choi, Kyle D. Perry, Lynette M. Smith, Xinlan Shi, Christine P. Hans et al. „Addition of Rituximab to Standard Chemotherapy Improves the Survival of Both the Germinal Center B-Cell–Like and Non–Germinal Center B-Cell–Like Subtypes of Diffuse Large B-Cell Lymphoma“. Journal of Clinical Oncology 26, Nr. 28 (01.10.2008): 4587–94. http://dx.doi.org/10.1200/jco.2007.15.9277.
Der volle Inhalt der QuelleCao, Yabing, Ying Huang, Sheng Ye und Tongyu Lin. „Prognostic impact of immunohistochemically defined germinal center B-cell and nongerminal center B-cell subtypes of diffuse large B-cell lymphoma in rituximab era.“ Journal of Clinical Oncology 30, Nr. 15_suppl (20.05.2012): e18517-e18517. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e18517.
Der volle Inhalt der QuelleHuang, Ying, Sheng Ye, Yabing Cao, Zhiming Li, Jiajia Huang, He Huang, Muyan Cai, Rongzhen Luo und Tongyu Lin. „Outcome of R-CHOP or CHOP Regimen for Germinal Center and Nongerminal Center Subtypes of Diffuse Large B-Cell Lymphoma of Chinese Patients“. Scientific World Journal 2012 (2012): 1–7. http://dx.doi.org/10.1100/2012/897178.
Der volle Inhalt der QuelleDunleavy, Kieron, Stefania Pittaluga, Myron S. Czuczman, Sandeep S. Dave, George Wright, Nicole Grant, Margaret Shovlin et al. „Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma“. Blood 113, Nr. 24 (11.06.2009): 6069–76. http://dx.doi.org/10.1182/blood-2009-01-199679.
Der volle Inhalt der QuelleWenzl, Kerstin, Bryce Manso, Yan W. Asmann, Matthew J. Maurer, Michelle Manske, Zhi-Zhang Yang, Susan L. Slager et al. „Whole-Exome Analysis Reveals Novel Somatic Genomic Alterations Associated with Cell of Origin in Diffuse Large B-Cell Lymphoma“. Blood 128, Nr. 22 (02.12.2016): 2935. http://dx.doi.org/10.1182/blood.v128.22.2935.2935.
Der volle Inhalt der QuelleDe Paepe, Pascale, Ruth Achten, Gregor Verhoef, Iwona Wlodarska, Michel Stul, Vera Vanhentenrijk, Marleen Praet und Chris De Wolf-Peeters. „Large Cleaved and Immunoblastic Lymphoma May Represent Two Distinct Clinicopathologic Entities Within the Group of Diffuse Large B-Cell Lymphomas“. Journal of Clinical Oncology 23, Nr. 28 (01.10.2005): 7060–68. http://dx.doi.org/10.1200/jco.2005.15.503.
Der volle Inhalt der QuelleDekker, Joseph D., Daechan Park, Arthur L. Shaffer, Holger Kohlhammer, Wei Deng, Bum-Kyu Lee, Gregory C. Ippolito et al. „Subtype-specific addiction of the activated B-cell subset of diffuse large B-cell lymphoma to FOXP1“. Proceedings of the National Academy of Sciences 113, Nr. 5 (19.01.2016): E577—E586. http://dx.doi.org/10.1073/pnas.1524677113.
Der volle Inhalt der QuelleWaller, Rosalie Griffin, Dennis P. Robinson, Anne J. Novak, Lisa M. Rimsza, Kerstin Wenzl, Rebecca L. King, Andrew L. Feldman et al. „Abstract 1181: Etiologic heterogeneity of genetic risk for DLBCL cell-of origin molecular subtypes“. Cancer Research 83, Nr. 7_Supplement (04.04.2023): 1181. http://dx.doi.org/10.1158/1538-7445.am2023-1181.
Der volle Inhalt der QuelleKim, Yu Ri, Soo-Jeong Kim, June-Won Cheong, Yundeok Kim, Ji Eun Jang, Jung Yeon Lee, Deok-Hwan Yang et al. „Upfront Autologous Stem Cell Transplantation Overcome the poor Prognosis of Non-Germinal Center Subtype of diffuse Large B-Cell Lymphoma in Patients with Advanced Stage and Elevated Serum Lactate Dehydrogenase“. Blood 124, Nr. 21 (06.12.2014): 3998. http://dx.doi.org/10.1182/blood.v124.21.3998.3998.
Der volle Inhalt der QuelleSoo, Joanne, David Matthew Kurtz, Florian Scherer, Alexander F. M. Craig, Michael C. Jin, Jason R. Westin, Davide Rossi et al. „Elucidation of distinct mutational patterns between diffuse large B cell lymphoma subtypes utilizing circulating tumor DNA.“ Journal of Clinical Oncology 35, Nr. 15_suppl (20.05.2017): 7538. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.7538.
Der volle Inhalt der QuelleXu-Monette, Zijun Y., Ling Li, John C. Byrd, Kausar J. Jabbar, Ganiraju C. Manyam, Charlotte Maria de Winde, Michiel van den Brand et al. „Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma“. Blood 128, Nr. 26 (29.12.2016): 3083–100. http://dx.doi.org/10.1182/blood-2016-05-715094.
Der volle Inhalt der QuelleFoureau, David, Lawrence J. Druhan, Nury M. Steuerwald, Sarah A. Baxter, Omotayo O. Fasan, Belinda R. Avalos und Nilanjan Ghosh. „Cytokine Profiling of ABC-Subtype and GCB-Subtype Diffuse Large B Cell Lymphoma: Systemic Nfkb Activation and Impact on Myeloid-Derived Suppressor Cells Distribution“. Blood 126, Nr. 23 (03.12.2015): 2666. http://dx.doi.org/10.1182/blood.v126.23.2666.2666.
Der volle Inhalt der QuelleHavranek, Ondrej, Jingda Xu, Stefan Koehrer, Zhiqiang Wang, Justin M. Comer, Lisa Becker, Allen F. Yi et al. „Molecular Aspects of Tonic B-Cell Receptor Signaling in Diffuse Large B-Cell Lymphoma Provide Biomarkers and Targets for Specific Inhibition“. Blood 128, Nr. 22 (02.12.2016): 779. http://dx.doi.org/10.1182/blood.v128.22.779.779.
Der volle Inhalt der QuelleTakizawa, Jun, Sadao Aoki, Akihito Momoi, Toshiki Kitajima, Masutaka Higashimura, Naoya Nakamura und Yoshifusa Aizawa. „BCL6 Rearrangement Detected by FISH Analysis Is a Poor Prognostic Factor in the “Non-Germinal Center Phenotype” of Diffuse Large B-Cell Lymphoma.“ Blood 108, Nr. 11 (16.11.2006): 4620. http://dx.doi.org/10.1182/blood.v108.11.4620.4620.
Der volle Inhalt der QuelleGupta, Mamta, Guangzhen Hu, Steven Offer, Matthew J. Maurer, Linda Wellik, Jing Jing Han, Ahmet Dogan, Robert B. Diasio und Thomas E. Witzig. „Expression but Not Promoter Hypermethylation of the Tyrosine Phosphatase PTPN6 Is Associated with Activated STAT3 and Inferior Prognosis in Diffuse Large B Cell Lymphoma Molecular Subtypes.“ Blood 120, Nr. 21 (16.11.2012): 2655. http://dx.doi.org/10.1182/blood.v120.21.2655.2655.
Der volle Inhalt der QuelleZhao, Fengyi, Lei Zhang, Yan Qin, Ming-Zhe Han, Xiaohong Han, Shiyu Jiang und Yuankai Shi. „Characterization of Methylation Patterns in Diffuse Large B Cell Lymphoma By Genome-Wide Methylation Analysis“. Blood 134, Supplement_1 (13.11.2019): 1243. http://dx.doi.org/10.1182/blood-2019-131656.
Der volle Inhalt der QuelleAlcoceba, Miguel, Elena Sebastián, Ana Balanzategui, Luis Marín, Santiago Montes-Moreno, Teresa Flores, Noemí Puig et al. „Preferential Acquision of N-Glycosylation Sites in the VDJ Region in Germinal Center B-Cell-Like Difusse Large B-Cell Lymphoma“. Blood 120, Nr. 21 (16.11.2012): 1589. http://dx.doi.org/10.1182/blood.v120.21.1589.1589.
Der volle Inhalt der QuelleNowakowski, Grzegorz S., Betsy LaPlant, William R. Macon, Craig B. Reeder, James M. Foran, Garth D. Nelson, Carrie A. Thompson et al. „Lenalidomide Combined With R-CHOP Overcomes Negative Prognostic Impact of Non–Germinal Center B-Cell Phenotype in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Phase II Study“. Journal of Clinical Oncology 33, Nr. 3 (20.01.2015): 251–57. http://dx.doi.org/10.1200/jco.2014.55.5714.
Der volle Inhalt der QuelleGozgit, Joseph M., Youngchul Song, Scott Wardwell, Sara Nadworny, Yaoyu Ning und Victor M. Rivera. „Potent Preclinical Activity of Ponatinib in Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma (GCB-DLBCL) Models“. Blood 126, Nr. 23 (03.12.2015): 4000. http://dx.doi.org/10.1182/blood.v126.23.4000.4000.
Der volle Inhalt der QuelleZettl, Andreas, Silvia Bea, George Wright, Itziar Salaverria, Philipp Jehn, German Ott, Wing-Chung Chan et al. „Chromosomal Imbalances in Germinal Center B-Cell-Like and Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Influence Gene Expression Signatures and Improve Gene Expression-Based Survival Prediction(the First Two Authors Contributed Equally to This Work).“ Blood 104, Nr. 11 (16.11.2004): 415. http://dx.doi.org/10.1182/blood.v104.11.415.415.
Der volle Inhalt der QuelleCao, Y., T. Lin, S. Wang, X. Fu, J. Xiao, J. Yi, H. Lin und Z. Guan. „A phase II study of R-CHOP in treatment of diffuse large B-cell lymphoma (DLBCL) subgroups“. Journal of Clinical Oncology 24, Nr. 18_suppl (20.06.2006): 17540. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.17540.
Der volle Inhalt der QuelleZhao, Peiqi, Huilai Zhang, Kai Fu, Xianhuo Wang, Lanfang Li, Zhengzi Qian, Lihua Qiu und Shiyong Zhou. „CD5 Expression Correlates with Inferior Survival and Enhances the Negative Effect of p53 Overexpression in Diffuse Large B Cell Lymphoma“. Blood 134, Supplement_1 (13.11.2019): 4117. http://dx.doi.org/10.1182/blood-2019-127666.
Der volle Inhalt der QuelleWang, Y. Lynn, Jiao Ma, Wei Xing, Pin Lu, Karen Dresser, Ailin Guo, Anjali Pandey, Pamela B. Conley, Hongbo Yu und Greg Coffey. „SYK and STAT3 Are Active in Diffuse Large B-Cell Lymphoma: Activity of Cerdulatinib, a Dual SYK/JAK Inhibitor“. Blood 124, Nr. 21 (06.12.2014): 926. http://dx.doi.org/10.1182/blood.v124.21.926.926.
Der volle Inhalt der QuelleFeng, Ru, Xiaolei Wei, Meng Xu, Fen Huang, Yongqiang Wei, Tong Zhao und B. Hilda Ye. „STAT3 Predicts Poor Outcome In Patients With Advanced Diffuse Large B Cell Lymphoma“. Blood 122, Nr. 21 (15.11.2013): 5069. http://dx.doi.org/10.1182/blood.v122.21.5069.5069.
Der volle Inhalt der QuelleQu, Jie, Matthew J. Maurer, James R. Cerhan, Anne J. Novak, Thomas M. Habermann, William R. Macon, Andrew L. Feldman et al. „Similar Phenotypes Demonstrated upon Initial Diagnosis and at Time of Recurrence in Relapsed DLBCL“. Blood 128, Nr. 22 (02.12.2016): 5299. http://dx.doi.org/10.1182/blood.v128.22.5299.5299.
Der volle Inhalt der QuelleEnnishi, Daisuke, Ali Bashashati, Saeed Saberi, Anja Mottok, Barbara Meissner, Merrill Boyle, Susana Ben-Neriah et al. „Frequent Genetic Alterations of PI3K-AKT Pathway and Their Clinical Significance in Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma“. Blood 128, Nr. 22 (02.12.2016): 607. http://dx.doi.org/10.1182/blood.v128.22.607.607.
Der volle Inhalt der QuellePrakash, Gaurav, Atul Sharma, Vinod Raina, Lalit Kumar und Mehar C. Sharma. „Outcome in different molecular subtypes of diffuse large B-cell lymphoma: Indian experience.“ Journal of Clinical Oncology 30, Nr. 15_suppl (20.05.2012): e18518-e18518. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e18518.
Der volle Inhalt der QuelleYunalda, Indah, Krisna Murt, Aida Farida, Ika Kartika und Erial Bahar. „Density of CD8 in Tumor Microenvironment of Diffuse Large B Cell Lymphoma Subtypes“. Majalah Patologi Indonesia 30, Nr. 2 (01.05.2021): 227–33. http://dx.doi.org/10.55816/mpi.v30i2.466.
Der volle Inhalt der QuelleTatterton, Dylan J., Benjamin Sale, Joel Allen, Maddy L. Newby, Giorgia Chiodin, Patrick J. Duriez, John Butler et al. „Oligomannose-Type Glycans in the Antigen Binding Site Identify Origin and Prognosis of Diffuse Large B Cell Lymphoma“. Blood 142, Supplement 1 (28.11.2023): 428. http://dx.doi.org/10.1182/blood-2023-188721.
Der volle Inhalt der QuelleFu, K., K. D. Perry, L. M. Smith, C. P. Hans, T. C. Greiner, W. C. Chan, D. D. Weisenburger et al. „Effect of addition of rituximab to CHOP on survival of patients in both the GCB and non-GCB subgroups of diffuse large B-cell lymphoma“. Journal of Clinical Oncology 25, Nr. 18_suppl (20.06.2007): 8040. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.8040.
Der volle Inhalt der Quelle